• 대한지역사회작업치료학회지
• /
• 제5권1호
• /
• pp.11-21
• /
• 2015

목적 : 본 연구는 지역사회 거주중인 뇌졸중 환자를 대상으로 자기 효능감과 수단적일상생활동작의 정도로 자립 정도를 알아보고 이에 따른 보호자의 삶의 질을 파악해봄으로써 지역사회 거주 뇌졸중 환자와 보호자간의 상관관계를 알아보고자 한다. 연구방법 : 2014년 5월 12일부터 2014년 5월 23일까지 총 2주간에 걸쳐 부산광역시에 위치한 3개 병원, 경상남도 거제시 소재 2개 병원에 외래 치료중인 MMSE-K 24점 이상인 뇌졸중 환자 138명을 대상으로 설문지(K-IADL, 자기효능감 측정도구, WHOQOL-BREF)를 이용해 자료를 수집하였으며 총 125부를 최종적으로 분석 하였다. 결과 : 125명의 환자 중 남자는 70명, 여자는 55명이었으며 평균연령은 58.72세(16세~82세)이었다. 대상자는 일반적 자기 효능감(p<0.01), 구체적 자기 효능감(p<0.01)과 보호자의 삶의 질 사이에서 유의한 상관관계를 나타내었고 수단적 일상생활 동작과 보호자의 삶의 질 사이에는 유의한 상관관계가 나타나지 않았다. 결론 : 일반적 자기효능감과 구체적 자기효능감이 보호자의 삶의 질과 상관관계를 보였으며, 일반적 특성중 경제상황 요인이 보호자의 삶의 질과 연관이 있는 것으로 나타났다. 결론적으로 뇌졸중 환자의 자기 효능감이 높을수록 보호자의 삶의 질도 높아지며 경제상황이 좋을수록 보호자의 삶의 질도 높게 나타났다. 그러나 뇌졸중 환자의 수단적 일상생활동작 정도와 보호자의 삶의 질과의 상관관계는 나타나지 않았다. 외래 치료중인 환자의 상황이 점점 만성화 되어 가고 있는 추세로 볼 때 현재 자신의 상태에 만족하지 않고 좀 더 발전 할 수 있는 자기 효능감 회복에 대한 치료적 계획이 수립되어져야 할 것이다.

• Journal of Chest Surgery
• /
• 제19권1호
• /
• pp.35-42
• /
• 1986

Prevention of thrombombolism after rosthetic cardiac valve replacement is essential for the patients. About 90% of patients are free of major and minor thromboembolic complications 5 year after replacement of cardiac valves with prosthetic devices when they are under control of anticoagulant therapy. Ticlopidine is a drug that alter platelet function to have an antithrombotic effect. It is an antiaggregating agent which inhibits primary platelet function to have an antithrombotic effect. It is an antiaggregating agent which inhibits primary platelet aggregation induced by ADP and increases the production of prostaglandin $D_{2}$. Aspirin in small doses inhibits platelet synthesis of prostaglandins by irreversibly blocking the enzyme cyclo-oxygenase. Platelet secretion and aggregation are impaired with Ticlopidine and Aspirin. the thromboembolic event sof 54 patient s who were treated with Ticlopidine and Aspirin after cardiac valve replacement were evaluated and compared with that of 79 patients who were treated with Wafarin and Aspirin after the same type of operation. The follow-up period ranged from 4 to 110 months (mean of 48 months). there were 11 major thromboembolic episodes including three deaths in the warfarin goup during mean follow-up period of 56 months. two cases of CVA and one hemoarthrosis were noted due to overdose of Warfarin. Inticlopidine group, there was only one fatal thromboembolic epdisode three month after mitral valve replacement during mean follow-up period of 18 months. Two episodes of hypermenorrhea resulting anemia ere noted in the ticlopidine group. We measured the parameters of platelet function in aggreagation curve of platelet with platelet aggregometer (chrono-log Aggregometer, Model No. 430) Aggregation test was performed with three final concentrations of epinephrine in 10 uM/L, ADP in 5uM/L. 28 patients with prosthetic cardiac valves and 35 healthy volunteers were subgrouped as follows to analyze the effect of antithrombotic drugs used. Group I ; 11 patients treated with 250-500 mg of ticlopidine and 0.5gm of Aspirin as a daily single dose after cardiac valve replacement (14 St. Jude Medical and 1 Carpentier-Edwards, 9 patients with atrial fibrillation among them) Group II ; 10 patients treated with 3-5 mg of Warfarin and 0.75 gm of Aspirin daily to prolong prothrombin time around 20 seconds for more than 6 months and single Aspirin dose was maintained afterward as a life-long regimes(3 St. Jude Medical, 1 Hall-Kaster and 7 Carpentier-Edwards valve, 9 patients in atrial fibrilation). Group III ; 7 patients who quit anticoagulant treatment (Warfarin + Aspirin) 6-12 months after the regime as group II (3 St. Jude Medical. 1 bjork-Shiley, 1 Hall-Kaster, 3 Carpentier-Edwards valve, 2 of them are with atrial fibrillation). Group IV ; 35 healthy vounteers (28 males and 7 females). The following results were obtained. 1. The mean maximal platelet aggregability in Group I induced by 10uM/L epinephrine was 15.6%, and 17.5 and 18.7% in BM in proportion to the induction by 5 and 10 uM/L ADP. 2. The mean maximal platelet aggregability in Group II induced by 10uM/L epinephrine was 16.5%, and 27.4 and 44.7% in BM in proportion to the induction by 5 and 10uM/L ADP. 3. The mean maximal platelet aggregability in group III induced by 10uM/L epinephrine was 65%, and 56.5 and 51.8% in BM in proportion to the induction by 5 and 10 uM/L ADP. 4. The mean maximal platelet aggregability in the normal subjects induced by 10 uM/L epinephrine was 64%, and 65 and 69% in Bm inproportion to the induction by 5 and 10 uM/L ADP. 5. Reversible change of platelet aggregation curve induced by 5 and 10uM/L was noted all of the patients in Group I. conclusion : Ticlopidine is an antiaggregating agent which inhibits primary platelet aggregation induced by ADP, and increases the production of prostaglandin $D_{2}$. Ticlopidine and Aspirin produced a significant inhibition of platelet in the presence of ADP and epinephrine in our study. Acccording to our brief experience, 250 mg of ticlopidine and low dose of Aspirin resulted synergistic superior effect to each drug alone in prevention of thromboembolism after prosthetic cardiac valve replacement.